| Data | Ora | Fonte | Titolo | Simbolo | Compagnia |
| 30/05/2024 | 13:00 | GlobeNewswire Inc. | Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024, and Provides Business Update | NASDAQ:ROIVW | Roivant Sciences Ltd |
| 16/05/2024 | 22:05 | GlobeNewswire Inc. | Roivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024, and Provide Business Update on Thursday, May 30, 2024 | NASDAQ:ROIVW | Roivant Sciences Ltd |
| 02/04/2024 | 13:00 | GlobeNewswire Inc. | Roivant Announces Positive NEPTUNE Study Results for Brepocitinib in NIU, as well as Board Authorization for up to $1.5 Billion Share Repurchase Program, Including Repurchase of Entire Sumitomo Pharma Stake for $648 Million | NASDAQ:ROIVW | Roivant Sciences Ltd |
| 13/02/2024 | 13:00 | GlobeNewswire Inc. | Roivant Reports Financial Results for the Third Quarter Ended December 31, 2023, and Provides Business Update | NASDAQ:ROIVW | Roivant Sciences Ltd |
| 30/01/2024 | 22:05 | GlobeNewswire Inc. | Roivant to Report Financial Results for the Third Quarter Ended December 31, 2023, and Provide Business Update on Tuesday, February 13, 2024 | NASDAQ:ROIVW | Roivant Sciences Ltd |
| 20/12/2023 | 22:30 | GlobeNewswire Inc. | Roivant Reports Positive Initial Phase 2 Results for Batoclimab in Graves’ Disease | NASDAQ:ROIVW | Roivant Sciences Ltd |
| 14/12/2023 | 15:00 | GlobeNewswire Inc. | Roche Completes Acquisition of Telavant from Roivant, Including Rights to Novel TL1A Directed Antibody (RVT-3101) for the Treatment of Inflammatory Bowel Disease | NASDAQ:ROIVW | Roivant Sciences Ltd |
| 28/11/2023 | 13:00 | GlobeNewswire Inc. | Roivant Announces Positive IMVT-1402 Initial 600 mg MAD Results that Confirm Best-in-Class Potential | NASDAQ:ROIVW | Roivant Sciences Ltd |
| 27/11/2023 | 14:00 | GlobeNewswire Inc. | Roivant and Priovant Announce Results from Phase 2 Study of Oral Brepocitinib in Systemic Lupus Erythematosus | NASDAQ:ROIVW | Roivant Sciences Ltd |
| 13/11/2023 | 13:00 | GlobeNewswire Inc. | Roivant Reports Financial Results for the Second Quarter Ended September 30, 2023, and Provides Business Update | NASDAQ:ROIVW | Roivant Sciences Ltd |
| 10/11/2023 | 14:00 | GlobeNewswire Inc. | Roivant Announces Appointment of Mayukh Sukhatme to Its Board of Directors | NASDAQ:ROIVW | Roivant Sciences Ltd |
| 30/10/2023 | 22:30 | GlobeNewswire Inc. | Roivant to Report Financial Results for the Second Quarter Ended September 30, 2023, and Provide Business Update on Monday, November 13, 2023 | NASDAQ:ROIVW | Roivant Sciences Ltd |
| 23/10/2023 | 07:00 | GlobeNewswire Inc. | Roche Enters Into a Definitive Agreement to Acquire Telavant Including Rights to Novel TL1A Directed Antibody (RVT-3101) for the Treatment of Inflammatory Bowel Disease From Roivant | NASDAQ:ROIVW | Roivant Sciences Ltd |
| 26/09/2023 | 12:00 | GlobeNewswire Inc. | Roivant Announces Positive Initial IMVT-1402 Phase 1 SAD and 300 mg Subcutaneous MAD Results | NASDAQ:ROIVW | Roivant Sciences Ltd |
| 11/09/2023 | 14:00 | GlobeNewswire Inc. | Roivant Announces Completion of Redemption of its Outstanding Warrants | NASDAQ:ROIVW | Roivant Sciences Ltd |
| 17/08/2023 | 22:05 | GlobeNewswire Inc. | Roivant Announces Redemption Fair Market Value in Connection with Redemption of its Outstanding Warrants | NASDAQ:ROIVW | Roivant Sciences Ltd |
| 14/08/2023 | 13:00 | GlobeNewswire Inc. | Roivant Reports Financial Results for the First Quarter Ended June 30, 2023, and Provides Business Update | NASDAQ:ROIVW | Roivant Sciences Ltd |
| 03/08/2023 | 22:05 | GlobeNewswire Inc. | Roivant to Report Financial Results for the Quarter Ended June 30, 2023, and Provide Business Update on Monday, August 14, 2023 | NASDAQ:ROIVW | Roivant Sciences Ltd |
| 02/08/2023 | 22:05 | GlobeNewswire Inc. | Roivant Announces Redemption of Outstanding Warrants | NASDAQ:ROIVW | Roivant Sciences Ltd |
| 27/07/2023 | 14:00 | GlobeNewswire Inc. | Telavant, a Roivant Company, Advances Inflammatory Bowel Disease Program with First Patient Dosed in Global Phase 2 Trial of Novel Anti-TL1A Antibody RVT-3101 in Crohn’s Disease | NASDAQ:ROIVW | Roivant Sciences Ltd |
| 14/07/2023 | 05:06 | KR Market News | 로이반트, 로슈에 $70억 가치의 장 치료제 판매 협상 중 | NASDAQ:ROIVW | Roivant Sciences Ltd |
| 11/07/2023 | 14:00 | GlobeNewswire Inc. | Roivant Ranks No. 25 on Fast Company’s Fifth Annual List of the 100 Best Workplaces for Innovators and is the Winner on the Science and Technology List as a Part of the Best Workplaces for Innovators Program | NASDAQ:ROIVW | Roivant Sciences Ltd |
| 28/06/2023 | 14:57 | GlobeNewswire Inc. | UPDATE -- Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2023, and Provides Business Update | NASDAQ:ROIVW | Roivant Sciences Ltd |
| 28/06/2023 | 13:00 | GlobeNewswire Inc. | Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2023, and Provides Business Update | NASDAQ:ROIVW | Roivant Sciences Ltd |
| 26/06/2023 | 22:05 | GlobeNewswire Inc. | Roivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2023, and Provide Business Update on Wednesday, June 28, 2023 | NASDAQ:ROIVW | Roivant Sciences Ltd |
| 22/06/2023 | 13:30 | GlobeNewswire Inc. | Roivant Reports Chronic Period Data for RVT-3101 from the TUSCANY-2 Phase 2b Study in Ulcerative Colitis, Demonstrating Improved Efficacy from the Induction to Chronic Period | NASDAQ:ROIVW | Roivant Sciences Ltd |
| 21/06/2023 | 23:00 | GlobeNewswire Inc. | Roivant to Host Investor Call at 8:00 AM ET on Thursday, June 22 to Review Results from the Chronic Period of TUSCANY-2, a Large Global Phase 2b Study of RVT-3101 (Anti-TL1A Antibody) in Ulcerative Colitis | NASDAQ:ROIVW | Roivant Sciences Ltd |
| 16/05/2023 | 13:00 | GlobeNewswire Inc. | Roivant Reports Positive Topline Results from ADORING 1, the Second Atopic Dermatitis Phase 3 Trial of VTAMA® (tapinarof) Cream, 1% in Adults and Children as Young as 2 Years Old | NASDAQ:ROIVW | Roivant Sciences Ltd |
| 28/03/2023 | 14:00 | GlobeNewswire Inc. | Covant and Boehringer Ingelheim Collaborate to Develop a Novel ADAR1 Inhibitor for Use in Cancer Patients | NASDAQ:ROIVW | Roivant Sciences Ltd |
| 15/03/2023 | 12:45 | GlobeNewswire Inc. | Roivant Reports Positive Topline Results from ADORING 2 Atopic Dermatitis Phase 3 Trial of VTAMA® (tapinarof) Cream, 1% Once Daily in Adults and Children as Young as 2 Years Old | NASDAQ:ROIVW | Roivant Sciences Ltd |